Mark McKenna, chairman and CEO at Mirador Therapeutics, speaks with Venrock partner Nimish Shah to discuss his most recent role at Prometheus Biosciences and the beginning of his new company, Mirador. McKenna shares a behind-the-scenes look into leading Prometheus during its acquisition by Merck, why he started Mirador Therapeutics, advice for other CEOs, what he values in a team and more.
Информация
- Подкаст
- ЧастотаЕжемесячно
- Опубликовано22 мая 2024 г., 12:00 UTC
- Длительность24 мин.
- ОграниченияБез ненормативной лексики